Advaxis Combination Trial with MedImmune Completes First Dose-Escalation Cohort
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 6/24/2026
- Nasdaq, S&P end lower as tech stocks fall
- Micron posts record profit as AI memory demand fuels explosive growth
- Brent settles at lowest since before start of Iran war as more tankers exit Hormuz
- All eyes on Micron earnings tonight as sell-off raises stakes for AI memory trade
- Alphabet added to Dow Jones Industrial Average, Verizon dropped
- Strong earthquake rocks north-central Venezuela, capital Caracas
- Needham Starts NeoVolta (NEOV) at Buy
- Wall Street ends lower on semiconductor selloff as AI spending concerns mount
- NextEra to discuss paying about $76 per share for Dominion, Bloomberg News reports
- Campbell Soup (CPB) Declares $0.39 Quarterly Dividend; 7.7% Yield
FBR Reiterates Advaxis (ADXS) at 'Outperform' Following Positive AXAL Combo Study with Durvalumab Data
March 29, 2016 11:46 AM EDTFBR & Co. reaffirms Advaxis, Inc. (Nasdaq: ADXS) at Outperform with a price target of $34 after the company... More
